Similar articles

• Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.

  Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. Byl B, et al. J Antimicrob Chemother. 2001 Aug;48(2):325-7. doi: 10.1093/jac/48.2.325. J Antimicrob Chemother. 2001. PMID: 11481316 No abstract available.
• [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].

  Halacová M, Průsa R, Kotaska K, Vávrová V. Halacová M, et al. Cas Lek Cesk. 2004;143(3):187-90. Cas Lek Cesk. 2004. PMID: 15134039 Czech.
• Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics.

  Allegaert K, Sherwin CM. Allegaert K, et al. Singapore Med J. 2010 Jan;51(1):88-9. Singapore Med J. 2010. PMID: 20200782 No abstract available.
• Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

  Ehsan Z, Clancy JP. Ehsan Z, et al. Future Microbiol. 2015;10(12):1901-12. doi: 10.2217/fmb.15.117. Epub 2015 Nov 17. Future Microbiol. 2015. PMID: 26573178 Free PMC article. Review.
• The amikacin research program: a stepwise approach to validate dosing regimens in neonates.

  Smits A, Kulo A, van den Anker J, Allegaert K. Smits A, et al. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):157-166. doi: 10.1080/17425255.2017.1234606. Epub 2016 Sep 21. Expert Opin Drug Metab Toxicol. 2017. PMID: 27623706 Review.